Integral Molecular Launches Measles Reporter Virus Particles to Accelerate Research for Therapeutics
PR Newswire
PHILADELPHIA, Nov. 18, 2026
PHILADELPHIA, Nov. 18, 2026 /PRNewswire/ -- Integral Molecular, the industry leader in providing reporter viruses to the vaccine industry, announces the launch of Measles Reporter Virus Particles (RVPs), expanding its portfolio of safe, non-replicative reagents for studying viral infection and neutralization. Measles cases have risen sharply in the United States, with more than 5,000 confirmed cases so far this year. The country has also officially lost its measles elimination status. While vaccination remains the best protection against measles, there is currently no FDA-approved antiviral therapy for active infection, creating an urgent need for tools that can accelerate research for new treatments.
Integral Molecular's Measles RVPs enable researchers to rapidly evaluate potential therapeutic antibodies for their ability to block viral entry without requiring the use of live measles virus. RVPs are pseudotyped virus particles engineered to display the envelope proteins of the corresponding virus while lacking the viral machinery needed to replicate or cause disease. This allows RVPs to be handled under standard laboratory conditions. Measles RVPs employ either a GFP or renilla luciferase reporter to provide a quantitative readout of activity for high-throughput testing. In contrast, conventional assays such as plaque reduction neutralization tests (PRNT) are labor-intensive, low-throughput, and require the use of live virus.
Integral Molecular's Measles RVPs provide researchers with the ability to:
- Measure antibody neutralization in a quantitative, high-throughput format
- Study inhibitors of viral entry under safe laboratory conditions (BSL-2)
- Screen previously characterized measles antibodies for possible use as therapeutics
- Scale studies with reliable supplies of critical reagents produced under ISO 9001-certified processes
Rapid Response to Emerging Threats
Measles RVPs are another example of Integral Molecular's ability to respond quickly to evolving viral outbreaks. With 25 years of experience, the company's molecular virology team has built adaptable platforms to rapidly produce safe reporter pseudovirus reagents for researchers studying emerging pathogens and new viral strains.
"When a new viral threat emerges, researchers need reliable tools quickly," said Benjamin Doranz, PhD, President and CEO of Integral Molecular. "We've seen several viral threats emerge this year, so in addition to launching Measles RVPs, we also developed safe reporter viruses for both Andes hantavirus and Bundibugyo ebolavirus in less than a month following sequence release. Being able to respond that fast means researchers can begin evaluating antibodies, vaccines, and other countermeasures without losing critical time."
Integral Molecular supports virology programs from R&D through clinical development with both off-the-shelf and customizable reagents. Explore our full array of virology products and services.
About Integral Molecular Virology
Integral Molecular's Virology business unit (virology.integralmolecular.com) streamlines vaccine and antiviral research with validated, ready-to-use critical reagents. Drawing on 25 years of experience and expertise spanning more than 100 viruses across 12 viral families, the company provides safe reporter viruses and customized reagents produced using scalable, ISO 9001-certified processes. Its solutions support vaccine programs worldwide, from early research through clinical development.
Follow Integral Molecular on LinkedIn
Press Contact
Integral Molecular
Soma Banik, PhD
Director of Public Relations
215-966-6061
info@integralmolecular.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/integral-molecular-launches-measles-reporter-virus-particles-to-accelerate-research-for-therapeutics-302943116.html
SOURCE Integral Molecular

